| DB11095 | Desirudin | Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery. |
| DB11242 | Gelatin | Not Available |
| DB11298 | Thioredoxin | Not Available |
| DB11300 | Thrombin | Not Available |
| DB11311 | Prothrombin | For use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. Prothrombin is administered as part of a cocktail containing several coagulation factors. |
| DB11312 | Protein C | Not Available |
| DB11330 | Factor IX Complex (Human) | Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy. |
| DB11569 | Ixekizumab | Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| DB11595 | Atezolizumab | For the treatment of patients with locally advanced or metastatic urothelial carcinoma who: 1) have disease progression during or following platinum-containing chemotherapy, and 2) have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. |
| DB11598 | Antithrombin III human | Antithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism |
| DB11621 | Human Varicella-Zoster Immune Globulin | Indicated for preventing and reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals within 4 days of exposure to varicella zoster virus. |
| DB11646 | Conatumumab | Not Available |
| DB11653 | Bremelanotide | Not Available |
| DB11657 | Tabalumab | Not Available |
| DB11668 | Rusalatide acetate | Not Available |
| DB11680 | Ficlatuzumab | Not Available |
| DB11685 | Figitumumab | Not Available |
| DB11690 | Vonapanitase | Not Available |
| DB11695 | Carnosine | Not Available |
| DB11700 | Setmelanotide | Not Available |
| DB11714 | Durvalumab | Durvalumab is indicated for patients with urothelial carcinoma, such as urinary bladder, urethra or ureter cancer. Patients with prolonged disease progression due to failed platinum-based chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment. Its clinical effectiveness is especially enhanced in PD-L1-positive patient groups [A19123]. |
| DB11715 | Bapineuzumab | Not Available |
| DB11724 | Bombesin | Not Available |
| DB11746 | Onartuzumab | Not Available |
| DB11756 | Solanezumab | Not Available |
| DB11767 | Sarilumab | Not Available |
| DB11771 | Tremelimumab | Not Available |
| DB11776 | Brodalumab | Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. |
| DB11788 | Neuropeptide Y | Not Available |
| DB11803 | Sirukumab | Not Available |
| DB11826 | Lampalizumab | Not Available |
| DB11834 | Guselkumab | Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. |
| DB11840 | Dalotuzumab | Not Available |
| DB11842 | Angiotensin Ii | Not Available |
| DB11849 | Emibetuzumab | Not Available |
| DB11856 | Ligelizumab | Not Available |
| DB11857 | Seribantumab | Not Available |
| DB11862 | Landogrozumab | Not Available |
| DB11866 | Romosozumab | Not Available |
| DB11945 | Avelumab | Indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). |
| DB11955 | Avotermin | Not Available |
| DB11959 | Crenezumab | Not Available |
| DB11972 | Rilotumumab | Not Available |
| DB11975 | TAK-448 | Not Available |
| DB11976 | Anifrolumab | Not Available |
| DB11988 | Ocrelizumab | Ocrelizumab is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis. |
| DB11997 | Interleukin-7 | Not Available |
| DB12003 | Thymosin beta-4 | Not Available |
| DB12023 | Benralizumab | Not Available |
| DB12034 | Gantenerumab | Not Available |
| DB12038 | Ulinastatin | Not Available |
| DB12053 | Visilizumab | Not Available |
| DB12056 | Trebananib | Not Available |
| DB12075 | Nagrestipen | Not Available |
| DB12088 | TT-232 | Not Available |
| DB12089 | Lorvotuzumab mertansine | Not Available |
| DB12090 | Patritumab | Not Available |
| DB12102 | Fulranumab | Not Available |
| DB12104 | Tarextumab | Not Available |
| DB12118 | Sotatercept | Not Available |
| DB12119 | Gevokizumab | Not Available |
| DB12126 | Bradykinin | Not Available |
| DB12132 | Vanutide cridificar | Not Available |
| DB12142 | Duligotuzumab | Not Available |
| DB12159 | Dupilumab | Dupilumab is a monoclonal antibody designed for the treatment of atopic diseases such as eczema. |
| DB12169 | Tralokinumab | Not Available |
| DB12182 | Binetrakin | Not Available |
| DB12189 | Etrolizumab | Not Available |
| DB12205 | Ganitumab | Not Available |
| DB12213 | Etaracizumab | Not Available |
| DB12240 | Polatuzumab Vedotin | Not Available |
| DB12246 | Inclacumab | Not Available |
| DB12250 | Cixutumumab | Not Available |
| DB12261 | Ascrinvacumab | Not Available |
| DB12274 | Aducanumab | Not Available |
| DB12330 | Blisibimod | Not Available |
| DB12335 | Tanezumab | Not Available |
| DB12349 | Dulanermin | Not Available |
| DB12363 | Dusigitumab | Not Available |
| DB12396 | Fresolimumab | Not Available |
| DB12409 | Vatreptacog alfa | Not Available |
| DB12431 | Muplestim | Not Available |
| DB12456 | Bococizumab | Not Available |
| DB12460 | Conbercept | Not Available |
| DB12489 | Mirvetuximab Soravtansine | Not Available |
| DB12495 | Selepressin | Not Available |
| DB12498 | Mogamulizumab | Not Available |
| DB12525 | Molgramostim | Not Available |
| DB12530 | Inebilizumab | Not Available |
| DB12534 | Mavrilimumab | Not Available |
| DB12560 | Blosozumab | Not Available |
| DB12568 | Tecemotide | Not Available |
| DB12584 | Bimagrumab | Not Available |
| DB12589 | Dacetuzumab | Not Available |
| DB12602 | Pentetreotide | Not Available |
| DB12609 | Tovetumab | Not Available |
| DB12616 | Sprifermin | Not Available |
| DB12620 | Nerve Growth Factor | Not Available |
| DB12652 | Endothelin-1 | Not Available |
| DB12684 | Aviscumine | Not Available |
| DB12698 | Ibalizumab | Not Available |
| DB12699 | Balugrastim | Not Available |
| DB12701 | Intetumumab | Not Available |
| DB12718 | Carlumab | Not Available |
| DB12726 | Monteplase | Not Available |
| DB12732 | Firategrast | Not Available |
| DB12734 | Demcizumab | Not Available |
| DB12738 | Tiplimotide | Not Available |
| DB12755 | Zoptarelin doxorubicin | Not Available |
| DB12775 | Abituzumab | Not Available |
| DB12777 | Somatoprim | Not Available |
| DB12807 | Naptumomab Estafenatox | Not Available |
| DB12815 | Crotedumab | Not Available |
| DB12820 | Concizumab | Not Available |
| DB12822 | Pancreatic Polypeptide | Not Available |
| DB12826 | Depatuxizumab | Not Available |
| DB12835 | Olipudase alfa | Not Available |
| DB12844 | Rontalizumab | Not Available |
| DB12845 | Amatuximab | Not Available |
| DB12849 | Clazakizumab | Not Available |
| DB12880 | Interleukin-10 | Not Available |
| DB12891 | Ozanezumab | Not Available |
| DB12893 | Sacituzumab govitecan | Not Available |
| DB12909 | Factor XIII (human) | Not Available |
| DB12938 | Isoxaflutole | Not Available |
| DB12943 | Milatuzumab | Not Available |
| DB12976 | Robatumumab | Not Available |
| DB13033 | Urocortin-2 | Not Available |
| DB13045 | Racotumomab | Not Available |
| DB13127 | Olokizumab | Not Available |
| DB13133 | Von Willebrand Factor Human | Not Available |
| DB13144 | Lenograstim | The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion.
GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome). |
| DB13148 | Coagulation factor X human | Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is indicated for subjects with hereditary Factor X deficiency for:
•On-demand treatment and control of bleeding episodes
•Perioperative management of bleeding in patients with mild hereditary Factor X deficiency |
| DB13149 | Protein S human | For use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors. |
| DB13150 | Coagulation factor VII human | May be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures. |
| DB13192 | Antihemophilic factor human | Not Available |
| DB00001 | Lepirudin | For the treatment of heparin-induced thrombocytopenia |
| DB00002 | Cetuximab | Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. |
| DB00003 | Dornase alfa | Used as adjunct therapy in the treatment of cystic fibrosis. |
| DB00004 | Denileukin diftitox | For treatment of cutaneous T-cell lymphoma |
| DB00005 | Etanercept | Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis. |
| DB00006 | Bivalirudin | For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned. |
| DB00007 | Leuprolide | For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty |
| DB00008 | Peginterferon alfa-2a | Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label]. |
| DB00009 | Alteplase | For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli |
| DB00010 | Sermorelin | For the treatment of dwarfism, prevention of HIV-induced weight loss |
| DB00011 | Interferon alfa-n1 | For treatment of venereal or genital warts caused by the Human Papiloma Virus |
| DB00012 | Darbepoetin alfa | For the treatment of anemia (from renal transplants or certain HIV treatment) |
| DB00013 | Urokinase | Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots. |
| DB00014 | Goserelin | Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. |
| DB00015 | Reteplase | For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
| DB00016 | Erythropoietin | For use in the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients. Also for use in the treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). Also for used to increase the yield of autologous blood from patients in a predonation program. When administered subcutaneously, Epoetin Zeta is equivalent to Epoetin Alfa in terms of clinical effectiveness. |
| DB00017 | Salmon Calcitonin | Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause. |
| DB00018 | Interferon alfa-n3 | For the intralesional treatment of refractory or recurring external condylomata acuminata. |
| DB00019 | Pegfilgrastim | Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant. |
| DB00020 | Sargramostim | For the treatment of cancer and bone marrow transplant |
| DB00021 | Secretin | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| DB00022 | Peginterferon alfa-2b | Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
|
| DB00025 | Antihemophilic factor, human recombinant | For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency. |
| DB00026 | Anakinra | For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). |
| DB00027 | Gramicidin D | For treatment of skin lesions, surface wounds and eye infections |
| DB00028 | Immune Globulin Human | IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases. |
| DB00029 | Anistreplase | For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
| DB00031 | Tenecteplase | For treatment of myocardial infarction and lysis of intracoronary emboli |
| DB00033 | Interferon gamma-1b | Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis. |
| DB00034 | Interferon Alfa-2a, Recombinant | For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection. |
| DB00035 | Desmopressin | Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia. |
| DB00036 | Coagulation factor VIIa Recombinant Human | For treatment of hemorrhagic complications in hemophilia A and B |
| DB00038 | Oprelvekin | Increases reduced platelet levels due to chemotherapy |
| DB00039 | Palifermin | For treatment of oral mucositis associated with chemotherapy and radiation therapy. |
| DB00040 | Glucagon recombinant | For treatment of severe hypoglycemia, also used in gastrointestinal imaging |
| DB00041 | Aldesleukin | For treatment of adults with metastatic renal cell carcinoma. |
| DB00042 | Botulinum Toxin Type B | For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. |
| DB00043 | Omalizumab | For treatment of asthma caused by allergies |
| DB00050 | Cetrorelix | For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation |
| DB00051 | Adalimumab | For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. |
| DB00054 | Abciximab | Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting. |
| DB00055 | Drotrecogin alfa | For reduction of mortality in patients with severe sepsis. |
| DB00056 | Gemtuzumab ozogamicin | Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). |
| DB00057 | Indium In-111 satumomab pendetide | For diagnosis of extrahepatic malignant cancers |
| DB00058 | Alpha-1-proteinase inhibitor | For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema. |
| DB00060 | Interferon beta-1a | For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum |
| DB00062 | Human Serum Albumin | For treatment of severe blood loss, hypervolemia, and hypoproteinemia. |
| DB00065 | Infliximab | To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis. |
| DB00066 | Follitropin | In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). |
| DB00067 | Vasopressin | For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding |
| DB00068 | Interferon beta-1b | Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks. |
| DB00069 | Interferon alfacon-1 | For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma |
| DB00070 | Hyaluronidase | For increase of absorption and distribution of other injected drugs and for rehydration. |
| DB00071 | Insulin Pork | For the treatment of type I and II diabetes mellitus. |
| DB00072 | Trastuzumab | For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. |
| DB00073 | Rituximab | For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. |
| DB00074 | Basiliximab | For prophylactic treatment of kidney transplant rejection |
| DB00075 | Muromonab | For treatment of organ transplant recipients, prevention of organ rejection |
| DB00078 | Ibritumomab tiuxetan | For treatment of non-Hodgkin's lymphoma |
| DB00081 | Tositumomab | For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular) |
| DB00083 | Botulinum Toxin Type A | For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating. |
| DB00086 | Streptokinase | For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae |
| DB00087 | Alemtuzumab | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| DB00089 | Capromab pendetide | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| DB00092 | Alefacept | As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis |
| DB00093 | Felypressin | For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential. |
| DB00095 | Efalizumab | For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. |
| DB00098 | Antithymocyte immunoglobulin (rabbit) | For prevention of renal transplant rejection |
| DB00099 | Filgrastim | Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen - it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies. |
| DB00102 | Becaplermin | For topical treatment of skin ulcers (from diabetes) |
| DB00103 | Agalsidase beta | For treatment of Fabry's disease (alpha-galactosidase A deficiency) |
| DB00105 | Interferon Alfa-2b, Recombinant | For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma. |
| DB00108 | Natalizumab | For treatment of multiple sclerosis. |
| DB00109 | Enfuvirtide | Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. |
| DB00110 | Palivizumab | For prophylaxis of respiratory diseases casued by respiratory syncytial virus. |
| DB00111 | Daclizumab | Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection |
| DB00112 | Bevacizumab | As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. |
| DB00113 | Technetium Tc-99m arcitumomab | For imaging colorectal tumors |
| DB00155 | L-Citrulline | Used for nutritional supplementation, also for treating dietary shortage or imbalance. |
| DB00183 | Pentagastrin | Used as a diagnostic aid for evaluation of gastric acid secretory function |
| DB00556 | Perflutren | Used as an ultrasound contrast imaging in cardiology and radiology. |
| DB00644 | Gonadorelin | For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation. |
| DB00666 | Nafarelin | For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis. |
| DB00781 | Polymyxin B Sulfate | For treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa. |
| DB00803 | Colistin | For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa. |
| DB00855 | Aminolevulinic acid | Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. |
| DB01111 | Colistimethate | For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa. |
| DB01229 | Paclitaxel | Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. |
| DB01257 | Eculizumab | For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. |
| DB01269 | Panitumumab | For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. |
| DB01270 | Ranibizumab | For the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
|
| DB01277 | Mecasermin | For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. |
| DB01278 | Pramlintide | For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. |
| DB01279 | Galsulfase | For the treatment of adults and children with Mucopolysaccharidosis VI. |
| DB01281 | Abatacept | For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children. |
| DB01284 | Tetracosactide | For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. |
| DB01285 | Corticotropin | For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. |
| DB01309 | Insulin Glulisine | For the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents. |
| DB01373 | Calcium | Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades. |
| DB01584 | Thyroglobulin | For the treatment of hypothyroidism (deficiency in the production of thyroid hormone). |
| DB01853 | Bacteriochlorophyll A | Not Available |
| DB02137 | Molybdenum Cofactor | Not Available |
| DB02261 | Platelet Activating Factor | Not Available |
| DB02638 | Terlipressin | Commonly used to stop bleeding of varices in the food pipe (oesophagus). |
| DB04894 | Vapreotide | For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea. |
| DB04899 | Nesiritide | For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. |
| DB04900 | Thymalfasin | Indicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization. |
| DB04901 | Galiximab | Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis. |
| DB04914 | G17DT | Intended for the treatment of various forms of cancer. |
| DB04921 | Dirucotide | For the treatment of multiple sclerosis (MS). |
| DB04925 | Desmoteplase | Investigated for use/treatment in cerebral ischemia and strokes. |
| DB04931 | Afamelanotide | Investigated for use/treatment in actinic keratosis, keratoses, skin cell studies, and skin infections/disorders. |
| DB04949 | Pexelizumab | For the treatment of inflammation during cardiac surgery. |
| DB04956 | Afelimomab | Investigated for use/treatment in sepsis and septicemia. |
| DB04958 | Epratuzumab | Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus. |
| DB04962 | Bectumomab | Investigated for use/treatment in lymphoma (non-hodgkin's). |
| DB04964 | Oregovomab | Investigated for use/treatment in ovarian cancer. |
| DB04985 | Tigapotide | For the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
|
| DB04988 | IGN311 | Intended for the treatment of various forms of cancer. |
| DB05006 | Adecatumumab | Investigated for use/treatment in breast cancer and prostate cancer. |
| DB05029 | Lancovutide | Investigated for use/treatment in cystic fibrosis and eye disorders/infections. |
| DB05032 | REV131 | Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts. |
| DB05084 | Abaloparatide | Investigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures. |
| DB05097 | Labetuzumab | Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab" |
| DB05098 | Leptin | Investigated for use/treatment in lipodystrophy and obesity. |
| DB05101 | Matuzumab | Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer. |
| DB05111 | Fontolizumab | Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders. |
| DB05115 | NN344 | Investigated for use/treatment in diabetes mellitus type 1 and 2. |
| DB05136 | Bavituximab | Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors. |
| DB05139 | CR002 | Investigated for use/treatment in nephropathy. |
| DB05155 | CR665 | Investigated for use/treatment in pain (acute or chronic). |
| DB05160 | Topsalysin | Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors. |
| DB05161 | Elafin | Investigated for use/treatment in inflammatory disorders (unspecified). |
| DB05209 | SYM001 | Investigated for use/treatment in thrombocytopenia. |
| DB05258 | Natural alpha interferon | Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma. |
| DB05259 | Glatiramer Acetate | For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis. |
| DB05276 | Hepatitis B Immune Globulin | Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications. |
| DB05299 | keyhole limpet hemocyanin | Investigated for use/treatment in bladder cancer and solid tumors. |
| DB05305 | Cintredekin Besudotox | Investigated for use/treatment in brain cancer. |
| DB05319 | oportuzumab monatox | Investigated for use/treatment in bladder cancer and head and neck cancer. |
| DB05332 | Romiplostim | Treatment of chronic immune thrombocytopenic purpura. |
| DB05336 | Obiltoxaximab | Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease. |
| DB05344 | Ciliary neurotrophic factor | Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified). |
| DB05394 | Corticorelin | Investigated for use/treatment in brain cancer and neurologic disorders. |
| DB05396 | Albinterferon Alfa-2B | Investigated for use/treatment in hepatitis (viral, C). |
| DB05405 | XTL-001 | Investigated for use/treatment in hepatitis (viral, B). |
| DB05437 | RIGScan CR49 | Investigated for use/treatment in colorectal cancer and solid tumors. |
| DB05446 | LJP 1082 | Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis. |
| DB05459 | Briakinumab | Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis. |
| DB05496 | Otelixizumab | Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders. |
| DB05578 | Ramucirumab | For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. |
| DB05595 | Farletuzumab | Investigated for use/treatment in ovarian cancer. |
| DB05679 | Ustekinumab | Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease. |
| DB05718 | Maxy-G34 | Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. |
| DB05773 | Trastuzumab emtansine | Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
|
| DB05777 | Thrombomodulin Alfa | Investigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis. |
| DB05793 | PRO-542 | Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. |
| DB05797 | TNX-901 | Investigated for use/treatment in allergic reaction. |
| DB05819 | NBI-6024 | Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications. |
| DB05833 | lymphotoxin beta receptor | Investigated for use/treatment in autoimmune diseases. |
| DB05875 | substance P | Investigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection. |
| DB05889 | Inotuzumab ozogamicin | Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). |
| DB05892 | RI 624 | Investigated for use/treatment in pain (acute or chronic). |
| DB05915 | MYO-029 | Investigated for use/treatment in muscular dystrophy. |
| DB06043 | Olaratumab | Olaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. |
| DB06101 | IMC-1C11 | Investigated for use/treatment in cancer/tumors (unspecified). |
| DB06168 | Canakinumab | Used in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). |
| DB06186 | Ipilimumab | Ipilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery. |
| DB06196 | Icatibant | Approved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections. |
| DB06273 | Tocilizumab | Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older. |
| DB06317 | Elotuzumab | Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. |
| DB06366 | Pertuzumab | Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. |
| DB06372 | Rilonacept | Rilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout. |
| DB06404 | Human C1-esterase inhibitor | For routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). |
| DB06602 | reslizumab | Investigated for use/treatment in esophageal disorders and pediatric indications. |
| DB06612 | Mepolizumab | Mepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history |
| DB06643 | Denosumab | Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. |
| DB06650 | Ofatumumab | Ofatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. |
| DB06655 | Liraglutide | For use in/treatment of diabetes mellitus type 2. |
| DB06663 | Pasireotide | For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option. |
| DB06674 | Golimumab | Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. |
| DB06681 | Belatacept | For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus. |
| DB06692 | Aprotinin | For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. |
| DB06719 | Buserelin | Buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction. |
| DB06785 | Ganirelix | For the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. |
| DB06788 | Histrelin | As the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer. |
| DB06791 | Lanreotide | Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2) |
| DB06825 | Triptorelin | Triptorelin is indicated for the palliative treatment of advanced prostate cancer. |
| DB08869 | Tesamorelin | Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. |
| DB08870 | Brentuximab vedotin | Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. |
| DB08879 | Belimumab | Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus. |
| DB08885 | Aflibercept | The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin. |
| DB08900 | Teduglutide | Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. |
| DB08902 | Raxibacumab | Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. |
| DB08904 | Certolizumab pegol | Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). |
| DB08935 | Obinutuzumab | Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. |
| DB09029 | Secukinumab | For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy. |
| DB09033 | Vedolizumab | Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. |
| DB09035 | Nivolumab | Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access. |
| DB09036 | Siltuximab | Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
| DB09037 | Pembrolizumab | Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:
patients with unresectable or metastatic melanoma.
patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.
patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. |
| DB09043 | Albiglutide | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| DB09045 | Dulaglutide | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| DB09046 | Metreleptin | Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. |
| DB09052 | Blinatumomab | Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
| DB09067 | Corticorelin ovine triflutate | Corticorelin is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. |
| DB09077 | Dinutuximab | Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. |
| DB09099 | Somatostatin | For the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established. |
| DB09103 | Ancestim | Not Available |
| DB09105 | Asfotase Alfa | Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP). |
| DB09107 | Methoxy polyethylene glycol-epoetin beta | For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required. |
| DB09109 | Turoctocog alfa | Not Available |
| DB09122 | Peginterferon beta-1a | For the treatment of patients with relapsing forms of multiple sclerosis. |
| DB09126 | Chorionic Gonadotropin (Human) | For the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for the treatment of selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males and for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins. |
| DB09141 | Protamine sulfate | Protamine sulfate is usually administered to reverse the large dose of heparin administered during certain surgeries, especially heart surgery. |
| DB09221 | Polaprezinc | Not Available |
| DB09222 | Fibrinogen Human | For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. |
| DB09264 | Idarucizumab | For use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. |
| DB09302 | Alirocumab | Alirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease. |
| DB09303 | Evolocumab | For the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering. |
| DB09312 | Antilymphocyte immunoglobulin (horse) | For prevention of renal transplant rejection and for the treatment of aplastic anemia. |
| DB09331 | Daratumumab | For the treatment of patients with multiple myeloma who have received at least three prior lines of therapy (a proteasome inhibitor (PI) and an immunomodulatory agent) or who are double-refractory to a PI and an immunomodulatory agent. This indication was approved by accelerated approval based on response rate. |
| DB09349 | Gastric intrinsic factor | Intrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to oral iron therapy. |
| DB09421 | Protirelin | Not Available |
| DB09559 | Necitumumab | Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC. |
| DB10516 | Casein | Not Available |